Abemaciclib with Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update
ASCO Guidelines
00:00
Intro
This chapter discusses the recent updates to the ASCO guidelines for using abemaciclib with endocrine therapy in high-risk early breast cancer. It highlights findings from the Monarchy study, showcasing the drug's effectiveness in enhancing invasive disease-free survival and its implications for future patient outcomes.
Play episode from 00:00
Transcript
